After the establishment of the SSc mouse model (Supplemental Figure 3A), the mice were divided into four groups and treated with PBS, a uPAR inhibitor, a uPAR agonist, or a PAI-1 inhibitor daily for an additional 3 weeks. This evidence concerns the gene SERPINE1 and systemic sclerosis.